A Phase 1/2A, Open Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948 (IRAK4i) as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
This research study is looking into a new medicine called CA-4948. It's for adults aged 18 and over who have acute myeloid leukaemia (AML) or a more serious type of myelodysplastic syndrome (MDS). This study has two main parts. The first part focuses on understanding if the medicine is safe and finding the right dose. Researchers will closely monitor for any side effects. The second part will then look at how well the medicine works in helping people with their AML or MDS. The goal is to see if CA-4948 can improve their condition. It's an important step in finding new ways to treat these blood cancers.
Em resumo
Sobre o que é este estudo?
This study is testing a new medicine called CA-4948 for two types of blood cancer: acute myeloid leukaemia (AML) and a more serious form of myelodysplastic syndrome (MDS). These conditions affect your blood-forming cells in the bone marrow.
The study is divided into two main parts. In the first part (called Phase 1), the main goal is to find out if the new medicine, CA-4948, is safe. The researchers will start with a very small dose and gradually increase it in different groups of people. They will carefully watch for any side effects and monitor your body's response with tests like ECGs (which check your heart) and blood tests. This helps them find the best dose that is both safe and has a good chance of working.
Once a safe dose is found, the study moves into the second part (called Phase 2a). Here, the main goal is to see how well CA-4948 works in treating AML or MDS. The researchers will be looking to see if the medicine helps improve your condition, for example, by reducing the number of cancer cells or helping your blood counts recover. They will compare the results against what they expect to see without this medicine. This is a very important step in developing new treatments that could help people with these conditions.
Pontos principais
- This study is for adults with certain blood cancers (AML or hrMDS).
- It's testing a new medicine called CA-4948.
- The study first checks for safety and then how well the medicine works.
- Participation involves regular clinic visits for checks and tests.
- You will know if you are receiving the study medicine.
- Você pode parar de participar a qualquer momento.
Quem pode ser elegível?
This study is for adults aged 18 years and older. Both men and women can take part.
You might be able to join this study if you have been diagnosed with acute myeloid leukaemia (AML) or a more serious type of myelodysplastic syndrome (MDS).
There will be other specific health requirements that you must meet to be considered for this study. Your doctor will carefully check these details to see if this study is suitable for you.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Você tem 18 anos ou mais?
- Have you been diagnosed with Acute Myeloid Leukaemia (AML) or a higher-risk Myelodysplastic Syndrome (MDS)?
- Are you willing to take study medicine by mouth?
- Are you able to attend regular clinic visits and tests?
O que envolve a participação?
If you join this study, you will be given the study medicine, CA-4948, by mouth. This is an 'open label' study, which means both you and your study doctor will know you are receiving CA-4948.
Throughout the study, you'll have regular visits to the clinic. At these visits, doctors and nurses will closely monitor your health. This will involve physical examinations, blood tests (to check your blood counts and how your organs are working), urine tests, and heart tests like ECGs. They will also ask you about any side effects you might be having.
The study involves several assessments to see how your body is reacting to the medicine and if your condition is improving. The total duration of your participation will depend on how you respond to the treatment and what the study protocol outlines, but you will be closely followed by the study team for an extended period.
Riscos e benefícios potenciais
Localizações (3)
- —Não verificadoAlemanha
- —Não verificadoEspanha
- —Não verificadoFrança
Perguntas frequentes
What is CA-4948?
CA-4948 is the new medicine being tested in this study for people with AML or MDS.
What is AML or MDS?
AML (Acute Myeloid Leukaemia) and MDS (Myelodysplastic Syndrome) are types of blood cancers that affect how your body makes blood cells.
What does 'open label' mean?
It means both you and the study doctors will know that you are receiving the study medicine, CA-4948.
Quanto tempo estarei no estudo?
The exact duration can vary, but you will have ongoing follow-up visits and monitoring as long as you are benefiting from the medicine or until the study requires.
What are 'Phase 1' and 'Phase 2a'?
Phase 1 is the first stage where they check if the medicine is safe and find the right dose. Phase 2a then looks at how well the medicine works.
Como saber mais
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Interessado em participar?
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.